新抗原脉冲树突状细胞疫苗在肿瘤免疫治疗中的作用  

Advances in the study of neoantigen pulsed dendritic cell vaccines in tumor immunotherapy

作　　者：王彤昕 张凡 闫鑫[1,2] 张雅婷 李玉民 Wang Tong-Xin;Zhang Fan;Yan Xin;Zhang Ya-Ting;Li Yu-Min(Gansu Provincial Key Laboratory of Gastrointestinal Tumors,Lanzhou,Gansu 730030,China;Department of Tumor Surgery,the Second Hospital of Lanzhou University,Lanzhou,Gansu 730030,China)

机构地区：[1]甘肃省消化系肿瘤重点实验室,甘肃兰州730030 [2]兰州大学第二医院肿瘤外科,甘肃兰州730030

出　　处：《解放军医学杂志》2024年第2期220-228,共9页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金(31770537);甘肃省重大科技项目(20ZD7FA003)。

摘　　要：新抗原脉冲树突状细胞疫苗(Neo-DCVac)是一种新型肿瘤免疫治疗手段。新抗原是指肿瘤细胞突变产生的具有较强免疫原性和肿瘤特异性的肽段。Neo-DCVac是基于新抗原被树突状细胞摄取、加工后递呈并激活T细胞引发机体免疫反应,从而发挥抗肿瘤作用。在高通量测序基础上发展而来的个体化Neo-DCVac有望成为肿瘤精准免疫治疗的新方向。本文从个体化Neo-DCVac构建、在实体瘤中联合治疗的临床应用、适宜接种人群和目前存在的局限性等方面进行综述,旨在为肿瘤免疫治疗的相关研究提供参考。Neoantigen pulsed dendritic cell vaccine(Neo-DCVac)is a new type of tumor immunotherapy.Neoantigen is strong immunologic and tumor-specific mutated peptides expressed in a tumor.Neo-DCVac is a therapeutic modality based on the uptake and processing of neoantigens by dendritic cells and their delivery and activation of T cells to trigger the body's immune response for anti-tumor effects.The development of individualized Neo-DCVac based on high-throughput sequencing is expected to be a new direction for precision immunotherapy of tumors.In this review,we discuss construction of individualized Neo-DCVac,clinical application of combination therapy in solid tumors,suitable population for vaccination and the current limitations of Neo-DCVac,aiming to provide a theoretical reference for research on tumor immunotherapy.

关 键 词：新抗原 树突状细胞疫苗 肿瘤 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]